Molecular basis for a polymorphism of human Fc gamma receptor II (CD32) by unknown
1Abbreviations used in this paper . HR, high responder; LR, low re-
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Summary
The IgG Fc receptor II on human monocytes is polymorphic in its ability to bind mIgG1, and
its isoelectric focusing pattern. To study the molecular basis of this polymorphism, a cDNA
library from cell line K562, expressing two different allelic forms (high responder [HR] and
low responder [LR]) of FcyRII, was used for cDNA cloning. We report the isolation and
identification of different FcyRII cDNA clones, comprising the LR form of FcyRII, as was
evident from studies using a new HRspecific anti-FcyRII mAb 41H16, and from rosetting
experiments. Sequence analysis revealed that HR and LR forms differ by two amino acids, both
located in the external domain. In the cloned LR form, a glutamine is substituted by a tryptophan
residue at as position 27, located in the first Ig-like domain, and an arginine residue by a histidine
residue at as position 131 in the second Ig-like domain. Furthermore, an FcyRII cDNA clone
was isolated with a deletion of 123 bp, overlapping the predicted transmembrane segment. Data
showing the presence of an alternatively spliced mRNA detectedby using polymerase chain reaction
(PCR) might suggest the existence of a soluble form of the human FcyRII, in addition to the
membrane-bound forms.
Rceptors for the Fc region of IgG, FcyR, mediate im-
portant regulatory and effector functions within the im-
mune system. FcyR are heterogeneous and three classes have
been described on humanleukocytes, FcyRI (CD64), FcyRII
(CD32), and FcyRIII (CD16). They can be distinguished
on the basis of molecular weight, cellular distribution, affinity
and specificity for IgG isotypes, and recognition by mAbs
(1, 2). During the last few years knowledge about these
receptors has increased rapidly, and cDNAs have been cloned
for all types (3-8) . FcyRII is a 40-kD glycoprotein with low
affinity for human IgG (K, N10-5-106 M-1), which also
binds mouse IgG1 (mIgG1). 1 Until now two allelic forms
of the human FcyRII couldbe distinguished based on differ-
ences in interaction with mouse IgG1, as observed in studies
on the induction of T cell proliferation, antibody-dependent
cellular cytotoxicity, and in rosetting experiments. In these
studies monocytes from different individuals interact either
strongly or weakly with mouse IgG1(high or low responder
individuals; HR or LR) (9-11).
To study the molecular basis of the functional polymor-
phism of FcyRII, a library from cell line K562, which ex-
presses two different allelic forms of FcyRII (apparent from
isoelectric focussing studies) (12),was used for cDNA cloning.
We obtained different cDNA clones comprising the LR form
of FcyRII, and found that LR FcyRII differed by two amino
acids(aa), located in the extracellular domain of the HR form.
Furthermore, one cDNA clone was isolated with a 123 by
deletion, overlapping the entire transmembrane segment,
which might encode a soluble form of FcyRII.
Materials and Methods
Cell Culture.
￿
K562, U937, and Jurkat cells were cultured in
RPMI 1640 medium supplemented with 5% FCS. Mouse L cells
and3T6were grownin DMEM/F10 (vol 1:1) containing 5% FCS.
MonoclonalAntibodies.
￿
Anti-FcyRI mAb used were 32.2 (cul-
ture supernatant) provided by Dr. C. Anderson (1), and 197.1
(purified Ig) from Medarex (Lebanon, NH) (13). Four mAb with
reactivity to FcyRII were used, IV.3 (purified Ig), agift from Dr.
C. Anderson (1), KuFc79 (ascites)from Dr. TMohanakumar(14),
CIKM5 (purified Ig) from Dr. G. Pilkington (15), and 41H16
(purified Ig) from Dr. T Zipf (16). We also tested anti-FcyRIII
mAb3G8 (purifiedIg)obtained from Medarex(Lebanon,NH) (17).
cDNA Clone Isolation and Characterization. A human K562
cDNA, Xgt10 library (a generous gift of Drs. Hoeijmakers and
Van Duin, Erasmus University, Rotterdam) was plated on Esche-
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Volume 172 July 1990 19-25rfchia coli BNN102; 106 PFU were screened in duplicate with three
'2P end-labeled oligonucleotides:
- 5' GAGCACGTTGATCCACGGGGGCTCAAGTTT 3',
- 5' GTAATCACCACTGTGACTGTGGTTTGC 3,
- 5' TCCAAGCCTGTGACCATCACTGTCCAAGTG 3'.
Plaques were lifted onto nitrocellulose filters (Millipore HATF 293
0.45 um), fixed at 80°C for 1 h and hybridized overnight in 10x
Denhardt's solution, 0.1% SDS, 3x SSC (20x SSC: 3 M NaCl,
0.3 M sodium citrate) 10% dextran sulphate, supplemented with
50 Ecg/ml denatured salmon spermDNA at 56°C. Washing was
carried out at stringency in 0.3 x SSC at 56°C. After autoradiog-
raphy, the positive plaques were plaque purified and rescreened,
using hybridization conditions as above. DNA was prepared from
clonal bacteriophages according standard procedures (18), and cDNA
inserts were isolated and subcloned into pTZ18 or 19 (Pharmacia
Fine Chemicals, Uppsala, Sweden) or into the expression vector
pcDX (19). Restriction enzyme analyses were performed and ap-
propriate fragments were subcloned into p1'218 or 19 vectors and
sequenced using the dideoxynucleotide chain termination method
(20) using either the M13 reverse primer or primer extension. DNA
data were analyzed using the pcgene program (Genofit, Grand-
Lancy, Switzerland). Hydropathicity profiles of the predicted as
sequences were computed using an interval of 13 aa.
Polymerase Chain Reaction.
￿
Poly(A)* RNA was isolated from
K562 andJurkat cells by the guanidinium isothiocyanate method,
followed by chromatography on oligo(dT)-cellulose (18), and cDNA
was synthesized using a cDNA kit (Promega, Leiden, The Nether-
lands). Plasmid DNAs were isolated according to standard proce-
dures (18). The PCR was performed using two specific FcyRII
primers, the first a 20-mer (5' GTGGAATTGG-CTTGGACAGT
3') overlapping 10 nucleotides (nt) at both sides of the deletion
of FcyRII cDNA clone pPW6 (see Results and Discussion), and
the second one a 19-mer (5' TCCAGGAGGGAGAAACCAT 3')
221 by upstream of this deletion. Amplification conditions were:
the initial template denaturing step (3 min at 99°C), followed by
a 35-fold repetitive cycle of 4 min at 65°C (annealing and exten-
sion) and 1.5 min at 99°C (denaturation) using 1 U DNA Taq-
polymerase (Perkin Elmer Cetus, Norwalk, CT), 10 mM dNTP
(Boehringer Mannheim, Mannheim, FRG), and 0.5 Ecg of both
primers in a final volume of 100 Ecl. After amplification the samples
were analyzed by electrophoresis on a 1.8% agarose gel and were
stained with ethidium bromide.
Transfection of L Cells.
￿
5 x 10' L cells were plated into mac-
rowells for 24 h. The cells were washed twice with TBS (25 mM
Tris-HCI pH 7.4, 137 mM NaCl, 5 mM KCI, 0.7 mM CaC12,
0.25 mM MgC12, 0.6 mM Na2HP0a), and 2 Fcg plasmid DNA
in 200 Ed TBS with DEAE-dextran (final concentration 50 Ag/ml)
were added per well. After30 min at 37°C, 0.5 ml DMEM/F10/5%
FCS supplemented with chloroquine (final concentration 50Icg/ml)
was added, and the mixture was incubated for 3 h at 37°C, the
plates were washed twice, and cells were allowed to grow for 48 h
in DMEM/F10 with 5% FCS. Cellswere harvested on day 4 and
used in immunofluorescence experiments.
Transfection of 3T6 Cells.
￿
To obtain stable transfectants, 10'
mouse 3T6 cells were seeded in culture flasks 1 d beforeDNA trans-
formation. Cellswere grown in F10/DMEM/5% FCS. The pcDX
vector containing pPW3 or pcD-16.2 as an insert (10 ug) was
cotransfected with PSV3gpt (2,ug) by using the CaP0c precipita-
tion method (21). After overnight exposition of the DNA, cells
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were treated with DMSO (10%, 30 min) and grown for 24 h on
nonselecting culture medium to allow expressionofthe transfected
markers. Selection for the dominant marker was performed in
modified MPA medium containing: F10/DMEM 1 :1, 5% FCS,
aminopterin (0.2 hg/ml), thymidine (5 Ecg/ml), xanthine (10
Ag/ml), hypoxanthine (15 Ecg/ml), mycophenolic acrd (MPA) (20
hg/ml), and deoxycytidine (2.3 ;cg/ml) . Selection medium was
replenished every 3-4 d. Clones were isolated after ti2-3 wk and
subclonedby limiting dilution. Expressionof FcyRII was determined
by staining with mAb IV.3. Stable transfectants expressing FcyRII
were maintained in MPA medium and used in rosetting assays.
Immunofluorescence.
￿
Expression of FcyR on cells was assayed by
indirect immunofluorescence, usingdifferent anti-FcyRmAb and FITC-
labelled F(ab')2 fraction of goat anti-mouse Ig antibody (Tago,
Burlingame, CA). Fluorescence was measured with a FACStar flow
cytometer (Becton & Dickinson).
EA-mIgG1 Roseuing Assay.
￿
EA rosette formation between stable
transfectants expressing either pcD16.2, or pPW3, or K562 cells
and human erythrocytes (HRBC) sensitizedwith anti-glycophorin
A mAb was performed as described before (10).
Results and Discussion
The external domain ofhumanFcyRII is homologous with
the mouse FcyR reactive with IgG2b and IgG1 .(22). Oligo-
nucleotides were constructed on the basis of the highest
number of homologous sequences between mouse (22) and
human (3-6) FcyRII with a maximum length of30 nt. Sev-
eral FcyRII cDNA clones were isolated from a K562 Xgt10
library using these probes, plaque purified, and subcloned.
K562 cDNA clones pPW3 and pPW6 were found to con-
tain 1.4- and 1.0-kb inserts, respectively (Fig. 1). Their spe-
cificity was confirmed by sequence analysis.
Fig. 1 A shows a physical map of two cDNA clones and
the location of the FcyRII coding region. An almost full-
length clone (pPW3) is identical to FvyRII cDNA clone pcD-
16.2 (3), except for 8 by in the coding region and 5 by in
the 3' untranslated region, and clone pPW3 is 37 by longer
at the 5' end (Fig. 1 B). A nt substitution (A into T) and
a deletion of 3 bp, resulting in the absence of an alanine (A)
residue, are located in the signalase cleavage site. The second
mismatch is located at as position 27 in the extracellular do-
main and encodes an as change of glutamine (Q into tryp-
tophan (W) provoked by the substitution of two nt, CA into
TG (Fig. 1 B). In the second Ig-like domain of the receptor
a point mutation (G into A) was found in clone pPW3,
resulting in an as change of arginine (R) into histidine (H)
(position 131) . Finally, in the coding region at position 179
a silent mutation has been found. Another isolated clone
(pPW16; data not shown) is not full-length at the 5' end,
but contains the same mutations at positions 27, 131, and
179 as clone pPW3. Furthermore, pPW16 includes a much
longer 3' untranslated region showing an alternate poly(A)
site selection, which is analogous to an FcyRII isolated from
a pheochromocytoma library (4).
Sequence analysis revealed an interesting deletion of 123
by in clone pPW6 (Fig. 1). Unfortunately, this clone is not
full length at the 5' end, but starts at as 53. Therefore, only
the third mutation site is known encoding an arginine res-N > M
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￿
Physical map of K562 FcyRII cDNA clones showing their relation to the restriction map and . coding sequence of human Fc-YRII
(A), and part of the nucleotide sequence of clone pPW3 (B) . (A) Arrows indicate polyadenylation signals (AATAAA), and open triangles desig-
nate deletions determined by sequence analysis. The open triangle marked in clone pPW6 represents a deletion of 123 by compared with pPW3,
and previously published human FcyRII cDNAs (3-6) . The open triangle marked in clone pPW3 represents a deletion of three by relative to
other FcryRII cDNAs (3-6) . Closed triangles in clone pPW3 point at mismatches compared to pcD-16.2, as detailed in (B), The upper row in B
shows sequence, and deduced aa, of clone pPW3 compared with homologous regions in pcD-16.2 (lower row) . The coding sequence of FcyRll
is depicted as an open box (A), wherein S is signal peptide, E-C is extracellular domain, TM is transmembrane segment, and C is intracellular
domain . The putative Winked glycosylation sites are depicted with asterisks, and cysteine residues with a small c. Abbreviations used for the as
are: L, leucine ; T, threonine ; C, cysteine; Q, glutamine, G, glycine; A, alanine, P, proline; H, histidine ; R, arginine; S, serine ; M, methionine;
and W tryptophan .
idue. pPW6 ends 3" at the same rat as pPW3 . The deletion
overlaps the entire transmembrane segment of the deduced
as sequence of the FcTRII cDNA clonespPW3 and pPW16,
starting at as 171 to 212 (VPSMG. . .KKRIS) of the receptor,
excluding the signal sequence. Comparison ofhydropathicity
profiles of the deduced as sequences of clones pPW6 (Fig.
2 A) and pPW3 (Fig . 2 B) clearly indicates the absence of
a transmembrane segment .
To exclude a cloning artifact for clone pPW6, we evalu-
ated the existence of corresponding mRNA in K562 cells.
Two oligonucleotides were synthesized, one overlapping 10
rat at both sides of the deleted region, and a second one 221
by upstream ofthis deletion. PlasmidDNAs containing clones
pPW3 or pPW6 as inserts were used as controls. Agarose
gel electrophoresis of the PCR-amplified reaction products
shows a clear band of 231 by using the plasmid-containing
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clone pPW6 (with deletion ; Fig . 3, lane 2), and no specific
band using pPW3 (Fig. 3, lane 3) . Obviously, these primers
can discriminate between the presence and absence of this
deletion . Expression ofmRNA transcripts encoding anFcyM
analogous to clone pPW6 in K562 cells is demonstrated by
a specific band of 231 by (Fig . 3, lane 4), which is absent
inJurkat cDNA (Fig . 3, lane S) . Because the deletion of 123
by excludes a transmembrane coding region, we postulate
that thismRNA encodes a solublehuman FcyR type II, most
likely created by alternative splicing. The possibility that al-
ternative splicing might be involved is supported by recent
studies showing an exon border located at position 212 (6) .
Soluble FcyRII molecules have previously been shown to
be present in normal murine serum (23) . Furthermore so-
called IgG-binding factors are reported, which are implicated
to play an important role in isotypic regulation (24) .x
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Figure 2 .
￿
Differences in hydropathicity profiles between the
deduced as sequences of pPW6 (A) and pPW3 (B) . Amino acid 1
represents the first as of the extracellular domain of the K562 Fc'YR11
clone pPW3 (B) . The first 52 as in A are indicated dashed, because
this part of the coding region is absent in clone pPW6 . The region
between the two arrows indicates the location of a transmembrane
segment (B) .
To analyze whether the isolated clones were encoding the
HR or LR FcyRII allelic form, murine L cells were tran-
siently transfected with cDNA clone pPW3, using thepcDX
expression vector (19) . We assessed the ability of these trans-
fectants, as well as two human cell lines U937 and K562,
to bind several anti-Fc-yR mAbs . One of the antibodies used
was mAb 411416, which is an FcyRII-specificmAb (16) with
a unique specificity, in that it recognizes an epitope expressed
only on the HR allelic form of FcyRII . This has recently
been demonstrated by one of us, usinghuman cells from well-
defined HR andLR individuals, typed by isoelectric focusing
analysis . It was possible to discriminate betweenLR and both
heterozygous and homozygousHR monocytes, platelets, as
well asPMNs using this mAb (25) . mAb IV.3 is also FcyRII
specific, but interacts with monocytes from both HR and
LR individuals with similar intensity (1) .
Isoelectric focusing data (Fig . 4) show similar fluorescence
intensity of U937 cells, expressing FcyRII in the homozy-
gousHR form, after incubation with mAbs IV.3 or 411416 .
K562 cells express FcyRII in a heterozygous manner, indi-
cated by the fluorescence level of 411416, which was -60%
of that obtained by using mAb IV3 . These findings are in
accordance with earlier isoelectric focusing studies ofFcyRII
on these cells (12) . L cells transiently transfected with K562
cDNA clonepPW3 show 2.1% positive transfectants, as de-
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Figure 3 .
￿
Detection of mRNA transcripts analogous to clone
pPW6 in K562 cells by using PCR . X DNA digested with Pstl was
used as marker DNA (lane 1) . The PCR reaction mixtures contained
250 ng cDNA from either K562 (lane 4), or Jurkat cells (lane 5),
and reaction mixtures for the controls ; 1 ng plasmid DNA of either
pPW6 (lane 2), or pPW3 (lane 3) . This experiment was repeated
thrice with comparable results.
termined by reactivity with mAb IV.3 . These transfectants,
however, were much less reactive with mAb 411416 (Fig. 4
B), indicating that K562 cDNA clone pPW3 encodes the
LR form of the polymorphic human FcyRII . Indirect iso-
electric focusing showed, furthermore, that L cells transfected
with pPW3bound anti-FcyRII mAbs CIKM5, and KuFc79,
but not anti-FcyRImAbs 32.2 or 197.1, or anti-FcyRII mAb
3G8 . Transient transfection of the U937 cDNA clone pcD-
16.2 revealed 2.8-2.9% positive transfectants as determined
by reactivity with both IV.3 and 411416 mAbs, which is con-
sistent with the HR phenotype of this FcyRII (Fig. 4 B) .
The functional activity of FcyRII was evaluated by roset-
ting experiments . Stable transfectants expressing equivalent
amounts ofFcyRII encoded by pPW3 or pcD-16.2, as deter-
mined by FACS analysis (data not shown), K562 cells, and
mock-transfected cells were used in these studies . Rosetting
with HRBC sensitized with graded amounts ofmIgG1 anti-U N
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￿
Expression of HR and LR forms of human FcyRII on K562, U937, routine L cells, and L cells transfected with clones pPW3 or
pcD-16.2. Relative immunofluorescence (A) o£ K562, U937, and L cells after binding mAb IV.3 (crosshatched bars), mAb 41H16 (black ban), or
second antibody only (control; open bars). L cells transiently expressing clones pPW3 or pcD-16.2 in the pcDX expression vector (B) incubated
with mAb IV.3, mAb 41H16, or second antibody, indicated as above. Data are representative of five independent experiments.
glycophorin A mAb resulted in striking differences between
the transfected HR (pcD-16 .2) and LR (pPW3) receptors.
K562 cells expressing both HR and LR FcyRII showed in-
termediate rosetting (Fig. 5) . Using F(ab)2 fragments of the
anti-glycophorin A mAb no rosetting was observed, nor with
mock-transfected cells. To exclude that the observed differ-
ences are due to a disfunction of expressed receptors, similar
rosetting experiments were performed using mIgG2a and
mlgG2b anti-glycophorin A switch variant mAb. Strong
rosetting was observed without differences between either
the FcyRII transfectants, or K562 cells (data not shown),
indicating the functionality of the receptors. Moreover, FcyRII
expressed by the three cell types were able to bind heat-
aggregated human IgG, as evaluated using immunofluores-
cence analysis (data not shown) . These results establish the
functional polymorphism of FcyRII with respect to mIgG1,
and show that this polymorphism does not result in differential
jnteraction with mlgG2a or mlgG2b antibodies.
From sequence analysis, immunofluorescence data obtained
with mAb 41H16, and rosetting experiments, we conclude
that the HR and LR forms of human FcyRII differ by three
aa. Since data on the NH2 terminus of the FcyRII glyco-
protein are lacking at present, we do not know whether the
missing alanine residue is located either at the end ofthe signal
peptide, or at the beginning of the external domain. Several
identical clones have been reported (3-6), each starting at an-
other as for the external domain, due to differences in com-
puter analysis. Comparison of these clones with clone pPW3
shows that the NH2-terminal part of FcyRII encoded by
pPW3 is identical to FcyRII cDNA clone HFc3.0 (5).
The differences responsible for the LR allelic form of
FcyRII, are most likely the conversions of a glutamine into
a tryptophan at position 27, and an arginine into a histidine
(position 131). These changes must constitute the basis for
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the observed polymorphic behavior in functional assays, iso-
electric focusing, as well as for a conformational epitope
change, leading to an altered reactivity with mAb 41H16.
The theoretical change in isoelectric point by these as differ-
ences of the unglycosylated protein is 0.16 (6.54 to 6.38).
This difference between HR and LR forms correlates with
the observed change in isoelectric focusing pattern (12).
Changing a strong into a weak basic as (position 131) might
be important for binding of mIgG1. The extent to which
each of these differences accounts for the functional or anti-
EA - rosetting (%)
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10 30 100 300 1000
antibody molecules /erythrocyte (00-3)
Figure 5.
￿
Rosette formation by transfectants expressing pPW3 (/;
LR), or pcD-16.2 (0; HR), or K562 cells (O) with HRBC sensi-
tized with different amounts mIgG1 anti-glycophorin A mAb.genic differences is currently being investigated. Recently,
the as change at position 131 has been reported by others
as theonly basisfor the polymorphism of FcyRII on human
monocytes (26). Provided this indeed is the only change in
theindividuals studiedby these authors, thefunctional poly-
morphism of FcyRII is composed of multiple allelic forms.
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In conclusion, our study shows that the functional poly-
morphism of membrane-bound human FcyRII is based on
at least two amino acid differences, a glutamine or trypto-
phan residue at as position 27, and an arginine or histidine
residue at position 131 in the extracellular domain.
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